Critical steps in the production of polyclonal and monoclonal antibodies: Evaluation and recommendations

ILAR Journal

Volumn 46, Issue 3, 2005, Pages 269-279

  Leenaars, Marlies ^a   Hendriksen, Coenraad F M ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Critical steps; Guidelines; Immunization; Monoclonal antibodies; Polyclonal antibodies; Production; Protocols

Indexed keywords

ALUMINUM SALT; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; VACCINE;

AGE; ANIMAL EUTHANASIA; ANIMAL USE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PURIFICATION; ANTIGEN SPECIFICITY; ARTICLE; ASCITES; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL PROTOCOL; DIAGNOSTIC VALUE; DRUG SYNTHESIS; EXPERIMENTAL ANIMAL WELFARE; HUMAN; HUMORAL IMMUNITY; HYBRIDOMA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INJECTION SITE; NONHUMAN; PRACTICE GUIDELINE; QUALITY CONTROL; SPECIES DIFFERENCE;

ANIMALIA;

EID: 21044456771     PISSN: 10842020     EISSN: None     Source Type: Journal    
DOI: 10.1093/ilar.46.3.269     Document Type: Article

References (53)

1. Amyx HL. 1987. Control of animal pain and distress in antibody production and infectious disease studies. JAVMA 191:1287-1289.
2. Anon. 1989. Code of Practice for the Production of Monoclonal Antibodies. Rijswijk, The Netherlands: Veterinary Public Health Inspectorate. AVMA [American Veterinary Medicine Association]. 2000. Report of the AVMA Panel on Euthanasia. JAVMA 218:669-696.
3. Borrebaeck CA, Danielsson L, Moller SA. 1988. Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes. Proc Natl Acad Sci U S A 85:3995-3999.
4. Brodeur BR, Tsang PS. 1986. High yield monoclonal antibody production in ascites. J Immunol Methods 86:239-241.
5. Brodeur BR, Tsang PS, Larose Y. 1984. Parameters affecting ascites tumour formation in mice and monoclonal antibody production. J Immunol Methods 71:265-272.
6. BVA/FRAME/RSPCA/UFAW [British Veterinary Association/Fund for the Replacement of Animals in Medical Experiments/Royal Society for the Prevention of Cruelty to Animals/Universities Federation for Animal Welfare]. 1993. Joint working group on refinement: Removal of blood from laboratory mammals and birds. Lab Anim 27:1-22.
7. CCAC [Canadian Council on Animal Care]. 2002. CCAC Guidelines on: Antibody Production, Ottawa ON: CCAC. (Available online: http://www.ccac.ca/english/gdlines/antibody/antibody.pdf).
8. Cox JC, Coulter AR. 1997. Adjuvants - A classification and review of the modes of action. Vaccine 15:248-256.
9. Erhard MH, Mahn K, Schmidt P, Oltmer S, Preisinger R, Zinsmeister P, Stangassinger M. 2000. Evaluation of various immunisation procedures in laying hens to induce high amounts of specific egg yolk antibodies. ATLA 28:63-80.
10. Dewar V, Voet P, Denamur F, Smal J. 2005. Industrial implementation of in vitro production of monoclonal antibodies. ILAR J 46:307-313.
11. FSU [Florida State University]. 1998. Laboratory Animal Program home page. Monoclonal Antibody Production in the Mouse - Ascites (http://www.fsu.edu/~FSULAR/ascites.html).
12. Gillette RW. 1987. Alternatives to pristane priming for ascites fluid and monoclonal antibody production. J Immunol Methods 99:21-23.
13. Griffen PS, Turton J, Andrews CM, Barrett P, Clarke CJ, Fung KW, Munday MR, Roman IF, Smyth R, Walshe K, York MJ. 2003. Markers of experimental acute inflammation in the wistar han rat with particular reference to haptoglobin and C-reactive protein. Arch Toxicol 77:392-402.
14. Guzman J, Frei K, Nadal D. 1995. In vitro immunization: Generation of neutralizing monoclonal antibodies to human interleukin-10. J Immunol Methods 179:265-268.
15. Hanly WC, Artwohl JE, Bennett BT. 1995. Review of polyclonal antibody production procedures in mammals and poultry. ILAR J 37:93-118.
16. Harlow E, Lane D. 1988. Adjuvants. In: Antibodies: A laboratory Manual. Cold Spring Harbor NY: Cold Spring Harbor Laboratory. p 96-124.
17. Hau J, Hendriksen CFM. 2005. Production of polyclonal antibodies: New technologies. ILAR J 46:294-299.
18. Hendriksen C, Hau J. 2003. Production of polyclonal and monoclonal antibodies. In: Handbook of Laboratory Animal Science. 2nd ed. Boca Raton: CRC Press LLC. p 391-411.
19. Hendriksen CFM. 1998. A call for a European prohibition of monoclonal antibody (MAb) production by the ascites procedure in laboratory animals. ATLA 26:523-540.
20. Hendriksen CFM, de Leeuw W. 1998. Production of monoclonal antibodies by the ascites method in laboratory animals. Res Immunol 149:535-542.
21. Home Office. 1991. Antibody production: advice on protocols for minimal severity. In: Report of the Animal Procedures Committee for 1991. London: HMSO. p 26. (Available online: Http://iacuc.cwru.edu; Http://www.hsus.org/search.jsp; Http://medicine.ucsd.edu).
22. Jackson LR, Trudel LJ, Fox JG, Lipman NS. 1999. Monoclonal antibody production in routine ascites. I. Clinical pathologic features. Lab Anim Sci 49:70-80.
23. Johnson DR. 1995. Murine monoclonal antibody development. In: Clifton NJ, ed. Methods in Molecular Biology. Vol 51. Totowa NJ: Humana Press. p 123-137.
24. Johnston BA, Eisen H, Fry D. 1991. An evaluation of several adjuvant emulsion regimens for production of polyclonal antisera in rabbits. Lab Anim Sci 41:15-21.
25. Köhler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
26. Leenaars PPAM, Claassen E, Boersma WJA. 1997. Antigens and antigen presentation. In: Lefkovits I, ed. Immunology Methods Manual. London: Academic Press Ltd. p 989-1013.
27. Leenaars PPAM, Hendriksen CFM, de Leeuw WA, Carat F, Delahaut Ph, Fischer R, Halder M, Hanly WC, Hartinger J, Hau J, Lindblad EB, Nicklas W, Outschoorn IM, Stewart-Tull DES. 1999. The Production of Polyclonal Antibodies in Laboratory Animal. The Report and Reconnnendations of ECVAM Workshop 35. ATLA 27:79-102.
28. (Available online: http://altweb.jhsph.edu/publications/ECVAM/ecvam35.htm).
29. Leenaars PPAM, Koedam MA, Wester P, Baumans V, Claassen E, Hendriksen CFM. 1998. Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Lab Anim 32:387-406.
30. Lindblad EB. 2000. Freund's adjuvants. In: O'Hagen DT, ed. Methods in Molecular Medicine: Vaccine Adjuvants - Preparation Methods and Research Protocols. Totowa NJ: Humana Press. p 79-102.
31. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. 2005. Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information sources. ILAR J 46:258-268.
32. Marx U, Embleton MJ, Fischer R, Gruber FP, Hansson U, Heuer J, de Leeuw WA, Logtenberg T, Merz W, Portelle D, Romette J-L, Straughan DW. 1997. Monoclonal antibody production. ECVAM Workshop report. ATLA 25:121-137.
33. McGuill MW, Rowan AN. 1989. Biological effects of blood loss: Implication of sampling volumes and techniques. ILAR News 31:5-20.
34. Moore JM, Rajah TV. 1994. Pristane retards clearance of particulate materials from the peritoneal cavity of laboratory mice. J Immunol Methods 173:273-278.
35. NIH [National Institutes of Health]. 1988. NIH intramural recommendations for the research use of complete Freund's adjuvant. (Grumstrupp-Scott J, Greenhouse DD). ILAR News 30:9.
36. NIH [National Institutes of Health]. 1997. Production of Monoclonal Antibodies Using Mouse Ascites Method (publication 98-01, November 17, 1997). Rockville: Office for Protection from Research Risks.
37. NRC [National Research Council]. 1996. Guide for the Care and Use of Laboratory Animals. 7th ed. Washington DC: National Academy Press. NRC [National Research Council]. 1999. Monoclonal Antibody Production. Washington DC: National Academy Press.
38. Peterson NC. 2000. Behavioral, clinical, and physiologic analysis of mice used for ascites monoclonal antibody production. Comp Med 50:516-526.
39. Peterson NC. 2005. Advances in monoblonal antibody technology: Genetic engineering of mice, cells, and immunoglobulins. ILAR J 46:314-319.
40. Pistillo MP, Sguerso V, Ferrara GB. 1992. High yields of anti-HLA Human monoclonal antibodies can be provided by SCID mice. Hum Immunol 35:256-259.
41. Schade R, Staak C, Hendriksen C, Erhard M, Hugl H, Koch G, Larsson A, Pollmann W, van Regenmortel M, Rijke E, Spielmann H, Steinbusch H, Straughan D. 1996. The production of avian (egg yolk) antibodies: IgY. In: The Report and Recommendations of ECVAM Workshop 21. ATLA 24:925-934. (Available online: http://altweb.jhsph.edu/publications/ECVAM/ecvam21.htm).
42. Smith DE, O'Brien ME, Palmer VJ, Sadowski JA. 1992. The selection of an adjuvant emulsion for polyclonal antisera in rabbits. Lab Anim Sci 42:599-601.
43. Stadler BM. 1999. Antibody production without animals. Dev Biol Stand 101:45-48.
44. Stewart F, Callander A, Garwes DJ. 1989. Comparison of ascites production for monoclonal antibodies in BALB/c and BALB/c derived cross-bred mice. J Immunol Methods 119:269-275.
45. Stewart-Tull DES. 1995. The theory and practical application of adjuvants. Chichester UK: John Wiley and Sons.
46. Stewart-Tull DES. 2000. Harmful and beneficial activities of immunological adjuvants. In: O'Hagen DT, ed. Methods in Molecular Medicine: Vaccine Adjuvants-Preparation Methods and Research Protocols. Totowa NJ: Humana Press. p 29-48.
47. Stills HF Jr. 1994. Polyclonal antibody production. In: Manning PJ, Ringlet DH, Newcomer CE, eds. The Biology of the Laboratory Rabbit, 2nd ed. San Diego: Academic Press Inc. p 435-448.
48. Stills HF Jr. 2005. Adjuvants and antibody production: Dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 46:280-293.
49. Stills HF Jr, Bailey MQ. 1991. The use of Freund's complete adjuvant. Lab Anim 20:25-30.
50. Takakura K, Yamada H, Weber H, Hollander VP. 1967. Studies on the pathogenesis of plasma cell tumors: Effects of sex hormones on the development of plasma cell tumors. Cancer Res 27:932-937.
51. UKCCCR [United Kingdom Co-ordinating Committee on Cancer Research]. 1998. Guidelines for the Welfare of Animals in Experimental Neoplasia. 2nd ed. Br J Cancer 77:1-10.
52. Vogel FR, Powell MF. 1995. A compendium of vaccine adjuvants and excipients. In: Powell MF, Newman MJ, eds. Vaccine Design: The Subunit and Adjuvant Approach., New York: Plenum Press. p 141-228.
53. Walvoort NC. 1991. Assessment of distress through pathological examination. In: Hendriksen CFM, Köeter HBWM, eds. Replacement, Reduction and Refinement: Present Possibilities and Future Prospects. Amsterdam: Elsevier. p 265-273.